Targeted expansion of cytotoxic T cells using IL-12 and CD137L supplementation enhances antitumor efficacy

The increasing success of allogenic Vδ2 T cell immunotherapy for the treatment of cancer has been demonstrated in recent studies. Vδ2 T cells recognize phosphoantigens, intermediates of the mevalonate pathway, through butyrophilin molecules, and they are not major histocompatibility complex (MHC) re...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Marta Sanz, Brendan T. Mann, Elyse K. McMahon, Alberto Bosque, Samuel Simmens, Natalia Soriano-Sarabia
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2025-06-01
Sarja:	Molecular Therapy: Oncology
Aiheet:	MT: Regular Issue gamma delta T cells Vd2 cells expansion cell therapy alendronate
Linkit:	http://www.sciencedirect.com/science/article/pii/S2950329925000657
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!